van der Heijde D, et al. - Tofacitinib, an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA) was evaluated regarding the efficacy, including inhibition of structural progression, and safety in patients with active RA and an inadequate response to methotrexate (MTX) in the phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial. Researchers reported month 24 data from the completed study in this work. They performed randomization of 797 patients 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched them to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Completion of 24 months of treatment was reported in 539 (67.6%). As per findings, patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX showed sustained clinical and radiographic treatment effects in months 12–24. The safety profile is consistent with that of other tofacitinib studies.